Loading
Doctors often use cancer drugs outside their approved use based on a hunch or a small study. Record what happens every time so the hunches become evidence.
Off-label use is common in oncology, especially for rare tumours and molecularly matched therapy, and the outcomes are almost never captured. DRUP (Netherlands) and TAPUR (ASCO) showed that a pragmatic protocol can turn off-label use into evidence and even into reimbursement (DRUP's personalised reimbursement model). The proposal extends this to all off-label anticancer use: a light-touch registration with structured indication, biomarker and outcome capture as a condition of reimbursement.
Shares Netherlands Cancer Institute (NKI-AvL), Tumour-agnostic (tissue-agnostic) approval, No incentive to repurpose cheap drugs, Real-world evidence.
Shares No incentive to repurpose cheap drugs, Real-world evidence, Weak real-world evidence and registries.
Shares No incentive to repurpose cheap drugs, Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries, Rare and paediatric cancers without markets.
Shares Tumour-agnostic (tissue-agnostic) approval, Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries, Rare and paediatric cancers without markets.
Shares Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries.